-
Heron Therapeutics NASDAQ:HRTX Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
Location: 4242 Campus Point Ct Ste 200, California, 92121, US | Website: herontx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
379.8M
Cash
67.35M
Avg Qtr Burn
-5.211M
Short % of Float
26.46%
Insider Ownership
0.69%
Institutional Own.
86.73%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNRELEF (bupivacaine and meloxicam) HTX-011 Details Post operative acute pain | Approved Quarterly sales | |
ZYNRELEF® Vial Access Needle ("VAN") Details Post operative acute pain | Approved Quarterly sales | |
ZYNRELEF (bupivacaine and meloxicam) HTX-011 Details Post operative acute pain | Approved Quarterly sales | |
Cinvanti Details Chemotherapy induced nausea and vomiting | Approved Quarterly sales | |
Sustol Details Chemotherapy induced nausea and vomiting | Approved Quarterly sales | |
APONVIE™ (HTX-019) Details Nausea and vomiting | Approved Quarterly sales |